Key Takeaways
- Pacifico Biolabs raised €7 million in Series A funding to scale up mycelium protein production.
- The company’s fermentation-based process aims to create sustainable protein solutions using existing brewery facilities.
- Funding will enhance production capacity, workforce, research, and market commercialization across Europe.
Funding Boost for Sustainable Protein Production
Pacifico Biolabs, a Berlin-based food technology startup, has secured €7 million in Series A funding to scale its mycelium protein production platform and develop its commercial launch strategy. This funding represents a critical step as the company aims to strengthen its presence in the booming alternative protein sector.
The startup focuses on producing protein derived from mycelium, which is the root-like structure of fungi. This innovative approach leverages a fermentation-based process designed to yield high-quality protein ingredients while significantly lowering the environmental impact compared to traditional animal agriculture. By utilizing biotechnology along with existing industrial infrastructure, Pacifico Biolabs seeks to create scalable protein solutions that can address future global food demands.
The raised capital will primarily be utilized to enhance production capabilities through its unique fermentation platform. Unlike traditional methods that require the construction of new manufacturing plants, Pacifico Biolabs collaborates with breweries that have surplus fermentation capacity, thereby optimizing underused industrial assets. This strategy is believed to decrease capital expenditures and hasten the time required to introduce sustainable protein products to the market.
The Series A financing attracted a consortium of investors with a keen interest in food innovation and sustainability, including Stray Dog Capital, TGFS Technologiegründerfonds Sachsen, Sprout & About Ventures, Simon Capital, FoodLabs, and a local brewery partner. This diverse group underscores the mounting interest in technologies that aim to bolster food system resilience while tackling environmental and supply chain issues.
The funding will aid Pacifico Biolabs in executing several strategic initiatives as it progresses. Besides increasing production capacity, the company plans to expand its workforce and enhance research and development efforts. It also aims to advance its commercialization activities in key European markets and refine its fermentation technology as it gears up for broader market integration.
Central to Pacifico Biolabs’ production strategy is the conviction that they can efficiently scale alternative proteins by utilizing existing fermentation infrastructure. By merging biotechnology with established industrial facilities, Pacifico seeks to establish a flexible manufacturing network that supports growth without the need for significant new construction. This approach also allows breweries to derive added value from their existing assets amid evolving market conditions.
Looking forward, Pacifico Biolabs intends to have its mycelium-based protein products available on retail shelves by late 2026. The company asserts that its technology will provide consumers with nutritious, sustainable protein options while helping to mitigate the environmental consequences of food production. The announcement highlights Pacifico’s commitment to blending European industrial infrastructure with biotechnological advancements to propel the development of next-generation protein products, thereby contributing to the transformation of the global food system.
The content above is a summary. For more details, see the source article.